# Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma

> **NCT00815308** · PHASE2 · COMPLETED · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 55 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** cetuximab (Erbitux)
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT00815308
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2011-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00815308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00815308, "Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00815308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*